Literature DB >> 18157698

Acromegaly: re-thinking the cancer risk.

Siobhan Loeper1, Shereen Ezzat.   

Abstract

Acromegaly is characterized by sustained elevation of circulating growth hormone (GH) and insulin-like growth factor I (IGF-I), and is clearly associated with increased morbidity and overall mortality mainly due to cardiovascular, metabolic, and respiratory diseases. Although cancer-related mortality varies widely amongst retroperspective studies, it appears to be consistently elevated mainly in patients with uncontrolled disease. We review individual tumor types including neoplasms of the colon, breast, prostate, and thyroid where in vitro, animal studies, and studies in non-acromegalic cancer patients have established a role for the GH/IGF-I axis in tumor progression and possibly initiation. We highlight deficiencies in data in acromegalic patients where the evidence is less convincing. Instead, we explore the hypothesis that acromegaly, independent of hormone secretion, is a disease that heralds genetic and/or epigenetic alterations predisposing to cancer risk elsewhere.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18157698     DOI: 10.1007/s11154-007-9063-z

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  192 in total

Review 1.  The oncogenic potential of growth hormone.

Authors:  Jo K Perry; B Starling Emerald; Hichem C Mertani; Peter E Lobie
Journal:  Growth Horm IGF Res       Date:  2006-11-13       Impact factor: 2.372

2.  Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly.

Authors:  P J Jenkins; V Frajese; A M Jones; C Camacho-Hubner; D G Lowe; P D Fairclough; S L Chew; A B Grossman; J P Monson; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

Review 3.  Epigenetic mechanisms of tumorigenesis.

Authors:  W E Farrell
Journal:  Horm Metab Res       Date:  2005-06       Impact factor: 2.936

4.  The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.

Authors:  P J Kaplan; S Mohan; P Cohen; B A Foster; N M Greenberg
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

5.  Enhanced growth of small bowel in transgenic mice expressing human insulin-like growth factor I.

Authors:  K Ohneda; M H Ulshen; C R Fuller; A J D'Ercole; P K Lund
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

6.  Insulin-like growth factor-I: autocrine secretion by human thyroid follicular cells in primary culture.

Authors:  B Tode; M Serio; C M Rotella; G Galli; F Franceschelli; A Tanini; R Toccafondi
Journal:  J Clin Endocrinol Metab       Date:  1989-09       Impact factor: 5.958

7.  De novo methylation of the p16INK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats.

Authors:  Igor P Pogribny; S Jill James
Journal:  Cancer Lett       Date:  2002-12-10       Impact factor: 8.679

8.  Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer.

Authors:  Manon van Engeland; Matty P Weijenberg; Guido M J M Roemen; Mirian Brink; Adriaan P de Bruïne; R Alexandra Goldbohm; Piet A van den Brandt; Stephen B Baylin; Anton F P M de Goeij; James G Herman
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

9.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  Increased epithelial cell proliferation in the colon of patients with acromegaly.

Authors:  A Cats; R P Dullaart; J H Kleibeuker; F Kuipers; W J Sluiter; M J Hardonk; E G de Vries
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

View more
  35 in total

Review 1.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

2.  Two birds with one stone: octreotide treatment for acromegaly and breast cancer.

Authors:  Young Kwang Chae; Mimi I Hu; Ruth L Katz; Mariana Chavez-MacGregor; Paul Haluska; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Amal Melhem-Bertrandt
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

3.  Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up.

Authors:  F Ceccato; G Occhi; N M Albiger; S Rizzati; S Ferasin; G Trivellin; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

4.  Serum proteome changes in acromegalic patients following transsphenoidal surgery: novel biomarkers of disease activity.

Authors:  Diana Cruz-Topete; Britt Christensen; Lucila Sackmann-Sala; Shigeru Okada; Jens Otto L Jorgensen; John J Kopchick
Journal:  Eur J Endocrinol       Date:  2010-11-08       Impact factor: 6.664

5.  Predictors of colonic pathologies in active acromegaly: single tertiary center experience.

Authors:  Raim Iliaz; Sema Ciftci Dogansen; Seher Tanrikulu; Gulsah Yenidunya Yalin; Bilger Cavus; Mine Gulluoglu; Filiz Akyuz; Sema Yarman
Journal:  Wien Klin Wochenschr       Date:  2018-07-30       Impact factor: 1.704

6.  Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.

Authors:  A Taslipinar; E Bolu; L Kebapcilar; M Sahin; G Uckaya; M Kutlu
Journal:  Med Oncol       Date:  2008-07-29       Impact factor: 3.064

7.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

8.  Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly.

Authors:  C L Ronchi; F Coletti; E Fesce; L Montefusco; C Ogliari; E Verrua; P Epaminonda; E Ferrante; E Malchiodi; V Morelli; P Beck-Peccoz; M Arosio
Journal:  J Endocrinol Invest       Date:  2009-04-29       Impact factor: 4.256

9.  Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.

Authors:  Serkan Dogan; Aysegul Atmaca; Selcuk Dagdelen; Belkis Erbas; Tomris Erbas
Journal:  Endocrine       Date:  2013-05-14       Impact factor: 3.633

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.